Dicyclomine

Introduction Overview

Generic Name

dicyclomine

Brand Name

Bentyl, Dibent, Dicyclocot

Dosage Form

intramuscular solution (10 mg/mL), oral capsule (10 mg), oral syrup (10 mg/5 mL), oral tablet (20 mg)

Drug Class

Anticholinergics / antispasmodics

Pharmacokinetics

Absorption:
Dicyclomine is administered via oral and intramuscular routes, with oral administration being the most common. Following oral ingestion, dicyclomine is readily absorbed from the gastrointestinal tract, with peak plasma concentrations generally achieved within 1 to 2 hours post-dose. The presence of food may delay the rate but not the extent of absorption. Oral bioavailability is moderate due to first-pass metabolism in the liver. Intramuscular injection bypasses the gastrointestinal tract, leading to more rapid systemic availability, which is particularly useful in patients unable to tolerate oral administration.

Distribution:
Dicyclomine distributes widely throughout the body after absorption. It is moderately bound to plasma proteins, allowing for adequate tissue penetration, particularly in smooth muscle tissues of the gastrointestinal tract, where its pharmacological action is targeted. The apparent volume of distribution is sufficient to suggest distribution beyond the vascular compartment. The drug's lipid solubility facilitates crossing cell membranes, ensuring access to muscarinic receptors in target tissues. There is limited data on penetration into the central nervous system, but some anticholinergic central effects have been reported, indicating CNS availability to a degree.

Metabolism:
Dicyclomine undergoes hepatic metabolism, primarily through oxidative pathways mediated by cytochrome P450 enzymes. The metabolites formed are generally inactive; however, the exact enzymatic pathways have not been fully elucidated. The metabolic process contributes significantly to the drug’s clearance, and hepatic impairment may alter dicyclomine plasma levels, necessitating caution and possible dose adjustments in patients with liver dysfunction. Metabolism follows first-pass kinetics for oral administration, reducing systemic availability.

Elimination:
The elimination of dicyclomine occurs primarily via renal excretion of metabolites, with only a small fraction of the unchanged drug excreted in urine. The plasma elimination half-life ranges from approximately 1.8 to 5 hours, supporting the dosing schedule of multiple daily administrations for maintaining therapeutic levels. Renal function influences the clearance rate; therefore, caution is advised in patients with renal impairment. The drug is eliminated through both metabolic degradation and excretory processes, with no evidence for significant biliary excretion or enterohepatic recirculation. Hemodialysis is unlikely to significantly remove dicyclomine due to its volume of distribution and protein binding.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 10 mg
- Oral tablet: 20 mg
- Oral syrup (liquid solution): 10 mg/5 mL
- Intramuscular injection solution: 10 mg/mL

Dosages for Adults and Adolescents:
- Oral administration: Initial recommended dose is 20 mg orally four times a day. After one week, maintenance dosing may be increased up to 40 mg orally four times a day based on clinical response.
- Intramuscular administration: 10 to 20 mg administered four times daily, reserved for patients unable to take oral medication.
- Duration of therapy typically ranges from 1 to 2 weeks.
- Therapy should be discontinued if efficacy is not observed within two weeks or if side effects necessitate reducing the dose below 80 mg per day.

Specific Patient Populations:
- Pediatric Use: Dicyclomine is contraindicated in children under 6 months old due to risk of serious adverse reactions and is generally not approved for use in those younger than 18 years.
- Older Adults: Increased sensitivity to anticholinergic effects such as dizziness, confusion, and hallucinations is reported; dosage adjustments and close monitoring are recommended.
- Renal and Hepatic Impairment: Limited data; caution advised with potential dose modification due to metabolism and elimination alterations.
- Pregnancy and Breastfeeding: Use during pregnancy only if clearly needed; contraindicated in breastfeeding due to risk of secretion in breast milk and adverse effects on the infant.

Mechanism Of Action

Dicyclomine is a tertiary amine anticholinergic agent that exerts its pharmacological effects primarily through the inhibition of muscarinic acetylcholine receptors in the smooth muscle of the gastrointestinal tract. By competitively antagonizing these receptors, dicyclomine blocks the action of acetylcholine at parasympathetic sites, which leads to relaxation of gastrointestinal smooth muscle and a subsequent reduction in spasms and motility.

At the molecular level, dicyclomine binds to M1 and M3 subtypes of muscarinic receptors, which are predominantly found on the surface of smooth muscles and glands within the digestive system. This blockade prevents the intracellular signaling cascade normally triggered by acetylcholine, such as phosphoinositide hydrolysis and increased intracellular calcium levels, resulting in decreased muscle contractility and secretory activity.

Clinically, the antispasmodic effect of dicyclomine reduces abdominal cramping, pain, and hypermotility associated with functional bowel disorders like irritable bowel syndrome. This mechanism distinguishes dicyclomine from other agents that work by altering pain signaling or inflammation. Unlike opioid antidiarrheals or anti-inflammatory drugs, dicyclomine directly modulates the autonomic nervous system influence on gut motility.

Comparatively, other anticholinergic agents like hyoscyamine share similar receptor targets and effects. However, dicyclomine's relatively favorable side effect profile and pharmacokinetic properties make it suitable for short-term management of IBS symptoms. Research studies demonstrate efficacy in reducing bowel spasms and abdominal pain, with randomized controlled trials supporting its use as part of symptomatic management protocols for functional bowel conditions.

Pharmacological Actions

Antimuscarinic agent blocking muscarinic receptors in the gastrointestinal tract
Smooth muscle relaxant leading to reduction of gastrointestinal spasms
Inhibits parasympathetic nerve impulses by preventing acetylcholine action
Reduces intestinal motility and secretions, alleviating cramping and pain
Exhibits mild central nervous system anticholinergic effects in some patients
Decreases GI tract smooth muscle hyperactivity associated with irritable bowel syndrome
Produces antispasmodic effects useful in functional bowel disorders
Modulates autonomic nervous system-mediated gut motility
Relieves symptoms of abdominal pain and cramping linked to bowel irritation
Contributes to decreased urgency and frequency of bowel movements

Therapeutic Or Clinical Uses

Treatment of functional bowel disorders, including irritable bowel syndrome (IBS)
Management of intestinal hypermotility and spastic colon
Relief of abdominal cramping and pain associated with bowel dysfunction
Adjunctive therapy for gastrointestinal spasms secondary to other conditions
Symptomatic treatment of irritable colon syndrome to improve patient comfort
Reduction of bowel spasm associated with diverticulosis and colitis in some cases
Use in patients unable to tolerate other antispasmodic therapies due to side effects
Short-term management of spasmodic gastrointestinal complaints
Treatment of pediatric functional bowel symptoms in patients over six months of age as clinically indicated
Adjunctive relieving agent during diagnostic gastrointestinal procedures to relax smooth muscles

Side Or Adverse Effects

Drowsiness and dizziness, potentially impairing alertness
Blurred vision due to anticholinergic effects on ocular accommodation
Dry mouth (xerostomia) caused by decreased salivary secretion
Nausea and gastrointestinal discomfort
Confusion, agitation, hallucinations, and mood changes especially in older adults
Tachycardia, palpitations, or cardiac arrhythmias including bradycardia or fluttering
Constipation or, conversely, diarrhea and worsening bowel symptoms
Difficulty swallowing or dysphagia
Muscle weakness or problems with coordination and balance
Local injection site reactions such as bruising, swelling, or pain
Signs of dehydration including dizziness, excessive thirst, or reduced urination
Allergic reactions manifesting as hives, facial swelling, or difficulty breathing
Potential exacerbation of glaucoma or urinary retention
Risk of heat stroke due to impaired sweating and thermoregulation
Rare but serious neurological events including seizures and loss of muscle control

Precautions

Use with caution in elderly patients due to increased susceptibility to CNS side effects
Avoid in patients with glaucoma due to risk of increased intraocular pressure
Contraindicated in patients with urinary retention or bladder outlet obstruction
Avoid use in patients with severe ulcerative colitis or gastrointestinal obstruction
Monitor carefully in individuals with severe cardiovascular conditions and active bleeding
Exercise caution in patients with myasthenia gravis, as anticholinergics may worsen symptoms
Not recommended during breastfeeding due to potential adverse effects on the nursing infant
Avoid use in pediatric patients under 6 months of age due to risk of serious adverse reactions
Caution advised in patients with liver or renal impairment — adjust dose as necessary
Avoid concurrent use with other drugs having anticholinergic properties to minimize toxicity
Monitor for signs of dehydration, especially during hot weather or exercise
Avoid driving or operating heavy machinery until drug effects on cognition and vision are known
Close observation when administered with medications that prolong QT interval or affect heart rhythm
Patients with enlarged prostate should report urinary symptoms promptly
Inform patients about possible side effects such as dry mouth and blurred vision

Warnings

Do not use in individuals with hypersensitivity to dicyclomine or its components
Not indicated for children under 18 years and contraindicated under 6 months of age
May cause serious anticholinergic side effects requiring immediate medical attention
Risk of severe adverse reactions including confusion, hallucinations, and muscle problems
Potential worsening of gastrointestinal symptoms such as severe constipation or diarrhea
Increased risk of heat stroke due to impaired thermoregulatory sweating
Concomitant use with other CNS depressants may exacerbate drowsiness and dizziness
Risk of worsening glaucoma and bladder obstruction symptoms during therapy
Overdose can result in life-threatening anticholinergic toxicity including seizures
Should be discontinued if therapeutic efficacy is not attained within two weeks
Use caution in patients with cardiovascular disease or history of stroke
Avoid use during breastfeeding as the drug may pass into milk and harm nursing infants
Monitor closely for signs of allergic reactions including facial or throat swelling
Patients should be warned not to take double doses if a dose is missed
Inform healthcare providers about all concurrent medications to avoid interactions

Contraindication

Hypersensitivity to dicyclomine or any component of the formulation
Glaucoma, particularly narrow-angle glaucoma due to risk of increased intraocular pressure
Bladder obstruction or severe urinary retention
Gastrointestinal obstruction including pyloric or duodenal obstruction
Severe ulcerative colitis due to exacerbation of symptoms
Gastroesophageal reflux disease (GERD) with severe symptoms
Serious heart conditions with active bleeding
Myasthenia gravis as anticholinergic agents can worsen muscle weakness
Breastfeeding women due to risk of drug transmission to infant
Children under six months of age based on safety concerns
Patients with a known history of hypersensitivity reactions to anticholinergic drugs
Patients with an ileostomy or colostomy where altered absorption or effects may occur

Drug Interactions

Additive anticholinergic effects when combined with other anticholinergic agents
Increased central nervous system depression when used with opioid analgesics or sedatives
Reduced absorption of oral dicyclomine when taken concomitantly with antacids
Increased risk of tachycardia or arrhythmias with concurrent use of certain heart medications
Potential exacerbation of glaucoma when taken with antiglaucoma medications
Possible enhanced CNS side effects when used with medications for anxiety, depression, or seizures
Worsening urinary retention when combined with drugs for overactive bladder or urinary disorders
Reduced effectiveness or increased side effects when used with Parkinson’s disease medications
Interactions with bronchodilators used in asthma treatment may alter therapeutic efficacy
Concomitant use with cold and allergy medications (e.g., antihistamines) may increase anticholinergic effects
Potential increased toxicity when combined with drugs impacting hepatic metabolism
Interactions with muscle relaxants could potentiate neuromuscular side effects
Herbal supplements with anticholinergic properties may potentiate adverse reactions
Patients should report use of all prescription, over-the-counter, and herbal products to healthcare providers
Drug interaction profiles are incomplete; caution is warranted when adding new medications

Preparations Of The Drug

Oral capsules containing 10 mg of dicyclomine
Oral tablets available in 20 mg strength
Oral syrup (liquid solution) standardized to 10 mg per 5 mL
Intramuscular injection solution with dicyclomine concentration of 10 mg/mL
Commercial preparations marketed under brand names such as Bentyl, Dibent, and Dicyclocot
Preserved and stored at room temperature, protected from moisture and heat
Available in prescription-only formulations with specified dosing devices for liquids
Injection preparation intended strictly for intramuscular administration, not intravenous use
Formulations designed to provide rapid onset (injection) or controlled oral dosing
Single-ingredient formulations with no combination products widely available
Packaged in various counts for outpatient and inpatient use
Manufactured under regulatory compliance ensuring consistency and quality
Prescribing information includes guidance on dose titration based on patient response
Dispensed with patient medication guides detailing usage, precautions, and side effects